Log in to your Inderes Free account to see all free content on this page.

EQL Pharma

55.40 SEK

-2.46 %

Less than 1K followers

EQL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-2.46 %

-13.84 %

-4.15 %

+9.27 %

-32.60 %

-32.60 %

+45.79 %

+47.73 %

+930.75 %

EQL Pharma operates in the pharmaceutical industry and focuses on the development, manufacturing and distribution of generic medicines. The company's products are aimed at healthcare institutions and patients who need cost-effective treatment options. The business is global with a primary presence in Europe, North America and Asia. EQL Pharma was founded in 2006 and is headquartered in Lund, Sweden.

Market cap

1.64B SEK

Turnover

549.82K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

8.5.

2026

Annual report '26

All

Press releases

3rd party

ShowingAll content types

Regulatory press release2/12/2026, 12:22 PM

EQL Pharma: Nomination committee for the 2026 Annual General Meeting

Press release2/4/2026, 8:19 AM

DNB Carnegie Access: EQL Pharma: Solid Q3 with branded-driven EBIT beat – worst behind it

Press release2/3/2026, 1:25 PM

DNB Carnegie Access: EQL Pharma: Q3 2025/26 initial: Beat driven by strong branded sales

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release2/3/2026, 1:15 PM

Bulletin from the extraordinary general meeting in EQL Pharma AB on 3 February 2026

Regulatory press release2/3/2026, 11:30 AM

EQL Pharma: Interim Report April - December 2025

Press release1/27/2026, 6:15 AM

DNB Carnegie Access: EQL Pharma: From reset to recovery – Q3 2025/26 preview

Press release1/15/2026, 10:40 AM

Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2025/26

Regulatory press release1/7/2026, 12:29 PM

Notice of extraordinary general meeting in EQL Pharma AB

Regulatory press release12/4/2025, 9:00 AM

EQL Pharma recruits Anne D Jensen as new Chief Sales Officer (CSO) and Carl Lindgren leaves his position as Chief Business Development Officer (CBDO)

Regulatory press release12/3/2025, 1:36 PM

EQL Pharma recruits Allan Sylvest Aasberg as new Chief Financial Officer (CFO)

Regulatory press release11/17/2025, 12:57 PM

EQL Pharma AB (publ) publishes prospectus and applies for admission to trading of bonds on the corporate bond list of Nasdaq Stockholm

Press release11/14/2025, 12:49 PM

EQL Pharma: Methenamine Hippurate (branded as Cystohipp©) have gained marketing approval in Germany

Press release11/6/2025, 7:08 AM

DNB Carnegie Access: EQL Pharma: Branded sales and restocking to drive recovery

Press release11/5/2025, 7:41 AM

DNB Carnegie Access: EQL Pharma: Weak set of numbers, as expected – Q2 initial take

Regulatory press release11/5/2025, 6:00 AM

EQL Pharma: Interim Report April - September 2025

Press release10/31/2025, 6:43 AM

DNB Carnegie Access: EQL Pharma: Temporary softness in Q2 as visibility recovers – Q2 preview

Press release10/22/2025, 9:27 AM

Invitation to presentation in connection with EQL Pharma's interim report, second quarter, 2025/26

Regulatory press release10/6/2025, 1:08 PM

EQL Pharma in process of recruiting new Chief Commercial Officer (CCO)

Regulatory press release9/30/2025, 8:00 AM

Change in number of shares and votes in EQL Pharma AB

Press release9/23/2025, 12:59 PM

EQL Pharma: Mellozzan® (melatonin) launched in the UK

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.